Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Treasury Shares (2022 - 2025)

Protagonist Therapeutics' Treasury Shares history spans 8 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 52.58% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 52.58%, while the annual FY2025 figure was $1.3 million, 1607.09% up from the prior year.
  • Treasury Shares for Q4 2025 was $1.3 million at Protagonist Therapeutics, up from $844708.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $1.3 million in Q4 2025 and bottomed at $105500.0 in Q4 2021.
  • The 5-year median for Treasury Shares is $421082.0 (2021), against an average of $471215.4.
  • The largest annual shift saw Treasury Shares plummeted 76.47% in 2022 before it surged 236.52% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $105500.0 in 2021, then surged by 89.1% to $199500.0 in 2022, then soared by 233.08% to $664491.0 in 2023, then grew by 27.12% to $844708.0 in 2024, then soared by 52.58% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Treasury Shares are $1.3 million (Q4 2025), $844708.0 (Q4 2024), and $664491.0 (Q4 2023).